A Phase 1 clinical trial of AVI-009
Latest Information Update: 22 Oct 2024
Price :
$35 *
At a glance
- Drugs AVI 009 (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions
- 22 Oct 2024 New trial record
- 16 Oct 2024 According to an Avicenna Biosciences media release, company prepare to launch a Phase 1 clinical trial of AVI-009 later next year.